Selective inhibition of SIRT2: A disputable therapeutic approach in cancer therapy

Selen Gozde Kaya; Gokcen Eren

doi:10.1016/j.bioorg.2023.107038

Selective inhibition of SIRT2: A disputable therapeutic approach in cancer therapy

Bioorg Chem. 2024 Feb:143:107038. doi: 10.1016/j.bioorg.2023.107038. Epub 2023 Dec 16.

Authors

Selen Gozde Kaya¹, Gokcen Eren²

Affiliations

¹ SIRTeam Group, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330 Ankara, Türkiye. Electronic address: selenkaya@gazi.edu.tr.
² SIRTeam Group, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330 Ankara, Türkiye. Electronic address: gokcene@gazi.edu.tr.

PMID: 38113655
DOI: 10.1016/j.bioorg.2023.107038

Abstract

Sirtuin 2 (SIRT2) is involved in a wide range of processes, from transcription to metabolism to genome stability. Dysregulation of SIRT2 has been associated with the pathogenesis and progression of different diseases, such as cancer and neurodegenerative disorders. In this context, targeting SIRT2 activity by small molecule inhibitors is a promising therapeutic strategy for treating related conditions, particularly cancer. This review summarizes the regulatory roles and molecular mechanisms of SIRT2 in cancer and the attempts to evaluate potential antitumor activities of SIRT2-selective inhibitors by in vitro and in vivo testing, which are expected to deepen our understanding of the role of SIRT2 in tumorigenesis and progression and may offer important clues or inspiration ideas for developing SIRT2 inhibitors with excellent affinity and selectivity.

Keywords: Antitumor; Cancer; SIRT2; Selectivity; Sirtuin.

Publication types

Review

MeSH terms

Humans
Neoplasms* / drug therapy
Sirtuin 2*

Substances

Sirtuin 2
SIRT2 protein, human